slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 76,741-76,770
Pages 3,679
Rows per page 30
Component
76,741-76,770 of 110,355
11
The slide uses a stacked bar chart to decompose unit costs into variable, fixed, and accrual components.Nikola | Results Presentation Deck | 18 slides · Nikola
Conference presentation Investor relations Beat · Satisfaction1 hit
13
The table includes truck deliveries, revenue, gross margin, R&D, SG&A, stock-based compensation, and CapEx.Nikola | Results Presentation Deck | 18 slides · Nikola
Conference presentation Investor relations 1 hit
15
Includes a footnote regarding regulatory and legal matters.Nikola | Results Presentation Deck | 18 slides · Nikola
Conference presentation Investor relations 1 hit
05
The slide uses a timeline-based structure to demonstrate operational momentum.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
08
The slide uses a standard pharmaceutical pipeline visualization format.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
09
The slide highlights the lack of clear standard of care in later lines of therapy, framing the problem for a potential new therapeutic intervention.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Pattern Hunter1 hit
10
The slide uses a 'Case Study' framework to validate the strategy by comparing it to the established success of Osimertinib in EGFR+ NSCLC.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
11
The slide uses a bar chart to segment the $3.1B market into specific drugs and categories.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizeLoop · Pattern Hunter1 hit
13
The slide uses a timeline-based framework to map clinical stages (1L, 2L, 3L+) against standard therapies and unmet needs.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
16
Includes a bar chart for brain penetrance and a dot plot for selectivity index across various mutations.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
22
Includes two patient case studies with MRI scans showing baseline vs follow-up results.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
24
The chart shows pharmacokinetic data across five dose cohorts, demonstrating that the 150mg dose consistently stays above the predicted CNS efficacy thresholds.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
25
The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and map the drug's value proposition to each.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
26
Includes a detailed table of patient cohorts and study objectives.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
28
The slide uses a timeline-based framework to contrast treatment options with clinical limitations.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
29
The slide uses a matrix-like structure to compare NVL-520's clinical profile against five competitors (Crizotinib, Entrectinib, Lorlatinib, Repotrectinib, Taletrectinib).Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
31
The slide presents a summary of a clinical trial, including patient eligibility criteria and a breakdown of patient cohorts by dose level.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
33
Includes a summary table of ORR and a waterfall plot of tumor regression.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
35
Data as of 13 Sep 2022. Includes list of specific adverse events by grade.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
36
RP2D = Recommended Phase 2 Dose; QD = once daily; MTD = Maximum Tolerated Dose.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
37
The slide uses a comparative structure to contrast the 2L+ (salvage) and 1L (frontline) market opportunities.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
38
The slide outlines a multi-cohort study design with specific patient populations (TKI-naive vs pre-treated) and objectives.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
25
The table includes specific line items for non-GAAP adjustments such as share-based compensation, interest, depreciation, and various one-time costs.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
26
Includes a footnote defining the Net Debt/EBITDA calculation.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
05
The slide uses a circular diagram to represent the 'Full Continuum of Care' with five distinct business segments.Orthofix | Investor Presentation Deck | 22 slides · Orthofix
Pitch deck Investor relations Beat · Problem1 hit
11
The slide highlights a TTM revenue of $733M with a breakdown of 28% Bone Growth Therapies, 57% Spinal Implants/Biologics/Enabling Tech, and 15% Orthopedics, alongside an 83/17 US/OUS split.Orthofix | Investor Presentation Deck | 22 slides · Orthofix
Pitch deck Investor relations 1 hit
15
Includes a specific footnote regarding preliminary unaudited revenue announced on Jan 9, 2024.Orthofix | Investor Presentation Deck | 22 slides · Orthofix
Pitch deck Investor relations Loop · Golden Circle1 hit
22
Includes reconciliation of non-GAAP financial measures related to the merger.Orthofix | Investor Presentation Deck | 22 slides · Orthofix
Pitch deck Investor relations 1 hit
04
The slide uses a dual-row timeline structure to show the evolution of the company.Pathward Financial | Investor Presentation Deck | 23 slides · Pathward
Pitch deck Investor relations Loop · Golden Circle1 hit
08
Includes a footnote regarding Frederick Moore's term ending.Pathward Financial | Investor Presentation Deck | 23 slides · Pathward
Pitch deck Investor relations Beat · Team1 hit